Online inquiry

IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5380MR)

This product GTTS-WQ5380MR is a type of mRNA modified with 5-Methyl-CTP & Pseudo-UTP, which ecodes the monoclonal antibody that targets env gene. The antibody can be applied in AIDS research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Pseudomonas aeruginosa; Homo sapiens
RefSeq NP_579894.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 155971
UniProt ID P04578
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5380MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14264MR IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RG-7116
GTTS-WQ12898MR IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA OPRX-106
GTTS-WQ602MR IVTScrip™ mRNA-Anti-RTN4, 6A3-IgG4(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 6A3-IgG4
GTTS-WQ7044MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Fab-12 variant Y0317
GTTS-WQ12030MR IVTScrip™ mRNA-Anti-ERBB2, MM-302(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MM-302
GTTS-WQ10390MR IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY2127399
GTTS-WQ4487MR IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-931699
GTTS-WQ7624MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN1029(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GEN1029
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW